(Q33292965)

25 July 2017

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation (English)

1 reference

25 July 2017

1 reference

Karen Quillen

3

0 references

Vaishali Sanchorawala

object named as

Vaishali Sanchorawala

1

0 references

Gheorghe Doros

5

object named as

Gheorghe Doros

2 references

ORCID Public Data File 2021

25 July 2017

Martha Skinner

2

1 reference

25 July 2017

Kathleen T Finn

4

1 reference

25 July 2017

David C Seldin

6

1 reference

25 July 2017

language of work or name

English

0 references

publication date

2 August 2007

1 reference

25 July 2017

1 reference

25 July 2017

110

1 reference

25 July 2017

10

1 reference

25 July 2017

3561-3563

1 reference

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

25 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Transplantation for amyloidosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Molecular mechanisms of amyloidosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2077307

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17673601

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17673601

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17673601

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2007-07-099481

1 reference

25 July 2017

1 reference

25 July 2017

1 reference